您目前的位置:院首页>首页 > 兼职博导

崔一民

 

崔一民

教授,博士生导师

研究领域:临床药学、临床药理

电话/传真:010- 66155258

电子邮箱:cuiym@pkufh.com

 

教育背景

日本自治医科大学,临床药理学专业博士(M.D&Ph.D)(2003)

北京医科大学,药学硕士(1998)

北京医科大学,药学理学学士(1991)

工作经历

2019.11至今北京大学临床药理研究所所长

2017.05至今北京大学第一医院临床试验中心主任

2007.03至今北京大学第一医院药学部主任

社会兼职

 

教育部高等学校药学类专业教学指导委员会副主任委员

国家卫生健康委药事管理与药物治疗学委员会委员

国家药典委员会委员

国家药品监督管理局仿制药质量和疗效一致性评价专家委员会委员

国家药品监督管理局药品审评中心咨询专家

中国药理学会副秘书长

中国药理学会临床药理专业委员会主任委员

中国医药创新促进会药物临床试验专业委员会主任委员

中国药学会产学研与创新工作委员会副主任委员

《Journal of Cinical Pharmacy and Therapeutics》主编

《中国临床药理学杂志》执行主编

《中国新药杂志》副主编

《临床药物治疗杂志》副主编

代表性论文

1.Su X, Wang H, Zhao N, Wang T*, Cui Y*. Trends in innovative drug development in China[J].Nat Rev Drug Discov. 2022.

Online ahead of print. IF:112.288

2.Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y*. Progress in the development of antiplatelet agents:

Focus on the targeted molecular pathway from bench to clinic[J].Pharmacol Ther, 2019, 203:107393. IF: 10.557.

3.Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y*. Target Drug-Calibrated Anti-Xa Activity Assays and

Expected Peak-Trough Levels in an Asian Population: A Multicenter Study. Am J Cardiovasc Drugs. 2021, 21(6):669-679. IF:3.383

4.Pang X#, Liu H#, He X, Ji T, Zhu Y*, Cui Y*. Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced

Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2[J]. Front Immunol. 2021, 12: 782335. IF: 8.786.

5.Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, Qian L, Deng H, Li H, Huo Y*.A Potential Long-Acting LDL-Cholesterol–Lowering

PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies. JACC: Asia. 2021, 1(3):411-415.

6.Zhao N, Liu Z, Xie Q, Wang Z, Sun Z, Xiang Q, Cui Y*. A Combined Pharmacometrics Analysis of Biomarker Distribution Under

Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.

Front Pharmacol. 2022,13:814724. IF: 5.988.

7.Wang Z, Zhao X, He P, Chen S, Jiang J, Harada A, Brooks S, Cui Y*. Idarucizumab Reverses Dabigatran Anticoagulant Activity

in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study[J]. Adv Ther. 2020, 37(9): 3916-28. IF: 3.842.

8.Zhou S, Wang Z, Liu Z, Mu G, Xie Q, Wang Z, Xiang Q*, Gong Y*, Cui Y*. Candidate Gene of NOS3, MMP3, AGT, and AGT1R and

Pathway Analyses for Platelet Reactivity and Clinical Outcomes of Repeat Revascularization After First PCI in Chinese Patients[J].

Cardiovasc Drugs Ther. 2021. Online ahead of print. IF: 3.947.

9.Su X, Pang X, Zeng X, Gao Y, Cui Y*, Wang H*. Analysis of Suspension of Clinical Trials for Drug Registration in China[J].

Front Pharmacol. 2020, 11: 598574. IF: 5.811.

10.Ma L, Xiang Q, Zhao N, Hu C, Fang M, Tan Y, Chen S, Wang Z, Liu P, Sun K, Li Y, Wu F, Tian H, Fang M, Zhao X, Wang G*, Cui Y*.

Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting

injection microsphere formulations[J]. Prog Neuropsychopharmacol Biol Psychiatry. 2021, 109: 110241. IF: 5.201.

11.Zhao N, Jia B, Zhao H, Xu J, Sheng X, Luo L, Huang Z, Wang X, Ren Q, Zhang Y, Zhao X, Cui Y. A First-in-Human Trial of GLS4,

a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with

or without Ritonavir in Healthy Adult Volunteers[J]. Antimicrob Agents Chemother, 2019, 64(1):e01686-19. IF: 4.904.

12.Zhang E#, Wu Y#, Chen C, Wei R, Zhang J, Xie H, Wei C, Ma L, Dong X, Li R, Zhou Y, Cui Y*, Wu Y*.

Effect of different initial rituximab regimens on B cell depletion in children with autoimmune neurological diseases[J].

Mult Scler Relat Disord. 2022, 59: 103510. IF: 4.808.

13.Zhang YH, Cui YM*. Gut microbiome metabolism drives the resolution of patients with COVID-19[J].

Gastroenterology. 2021. Online ahead of print. IF: 33.883. 

14.Xu L, Liu Y, Fan Z, Jiang Z, Liu Y, Ling R, Zhang J, Yu Z, Jin F, Wang C, Cui S, Wang S, Mao D, Han B, Wang T, Zhang G,

Wang T, Guo B, Yu L, Xu Y, Fu F, Liu Z, Wang S, Luo K, Xiang Q, Zhang Z, Liu Q, Zhou B, Liu Z, Ma C, Tong W, Mao J, Duan X*, Cui Y*.

Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy:

A Multicenter Cohort Study[J]. Front Oncol. 2021, 11: 606477. IF: 5.738.

15.Pang X, Zhang J, He X, Gu Y, Qian BZ, Xie R, Yu W, Zhang X, Li T, Shi X*, Zhou Y*, Cui Y*. SPP1 Promotes Enzalutamide Resistance

and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.

Oxid Med Cell Longev. 2021, 2021:5806602. IF:7.310.

荣誉奖励

 

2021年中国药学会科学技术奖一等奖

2021年全国科技系统抗击新冠肺炎疫情先进个人

2021年中国药学会最美科技工作者

2021年北京大学教学优秀奖

2019年中国药学发展奖创新药物奖突出成就奖

2018年吴阶平—保罗 杨森医学药学奖

2018年中国健康促进基金会药学紫晶奖

2017年药明康德生命化学研究奖学者奖

2016年中国医药创新最具影响力品牌评选-最具影响力药物临床研究领军人物

2014年北京大学仲外医学奖教金

2013年华夏医学科技奖三等奖

2013年中国药学发展奖创新药物奖突出成就奖

2012年阿斯利康杯中国医院药学奖创新奖

2012年中国药学会科学技术奖二等奖